Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could tame tough eczema by calming overactive immune cells

NCT ID NCT07711418

Recruiting now Disease control Sponsor: Nektar Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear or nearly clear the skin and reduce eczema severity over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called rezpegaldesleukin (NKTR-358) given as a shot under the skin
What this could lead to
If successful, this could provide a new treatment option for people with moderate-to-severe atopic dermatitis, potentially offering better symptom control with fewer side effects than current therapies.
What could go wrong
This is an early-stage Phase 3 trial, and the drug may not prove more effective than placebo. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nektar Investigative Site

    RECRUITING

    The Bronx, New York, 10455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.